Human BioSystems
Human BioSystems: HBS BioEnergy Appoints Mr. Claude Luster as President for its Renewable Energy Business
Corporate news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
HBS BioEnergy Appoints Mr. Claude Luster as President for its Renewable
Energy Business
Palo Alto, CA – October 9, 2006 – (OTCBB:HBSC) -Human BioSystems (“HBS”)
announced today that HBS BioEnergy (“HBS Bio”), a wholly owned subsidiary
of HBS, has appointed Mr. Claude Luster III as HBS BioEnergy’s President,
pursuant to the agreement signed between HBS and HBS Bio in September,
2006. Mr. Luster, the founder of EXL III Group Corporation,(EXL III) has
been involved in the final stages of developing and funding a 60-million
gallon Northern California ethanol facility which he will complete while
assuming his new duties with HBS BioEnergy.
“Among Mr. Luster’s first duties will be to develop necessary strategic
partners and consulting firms that HBS BioEnergy will need for the initial
stages of production,” stated Harry Masuda, CEO of Human BioSystems. “We
are pleased to have Claude as our President. He has the technical and
management background and the essential skills that HBS has been seeking,”
Mr. Masuda continued.
Mr. Luster was instrumental with EXL III’s current plans to develop up to
10 renewable fuels plants and 10 value added bioconversion facilities. EXL
III is also developing several new cost reduction processes for the
production of ethanol and biodiesel.
Prior to his involvement with the EXL III, Mr. Luster was President and CEO
of EXL Group a Portfolio Investment Company of Impact Capital Partners of
Oakland, CA which includes Wells Fargo and, Washington Mutual as Limited
Partners.
Mr. Luster has more than 30 years experience in the food-processing,
bio-conversion, energy and environmental industries and is considered one
of the food industry’s leading experts in the field of aseptic processing
and aseptic bulk plant operations. These involve highly complex processes
utilizing sophisticated equipment and manufacturing procedures. Ethanol
production utilizes processes and equipment that bear close resemblance to
those of the food processing industry.
Included amongst Mr. Luster’s credentials are the conception, development
and implementation of novel aseptic processes and protocols directed
towards developing Greenfield food processing and bio-conversion facilities
in the United States, Canada, China and Africa. He owned and operated
LusTek Labs and Consulting as well as serving as consultant in the food
processing, bio-conversion, energy and environmental industries. He was a
major shareholder in Helm Concentrates, Inc., which was subsequently sold
to ConAgra Foods, Inc.
Mr. Luster has held numerous technical, scientific and management positions
including Process Technician for General Foods, Inc., Process Operations
and Research Manager for Tri-Valley Growers, Fermentation Manager for
Miller Brewing Company, Vice President of Operations for Helm Concentrates,
Inc. and Technical Leader for Hunt-Wesson Foods, Inc. While at Helm
Concentrates Inc, Mr. Luster designed and supervised the construction of
one of the most sophisticated aseptic processing plants in California.
“I see HBS Bio as an innovative company, prepared to join the burgeoning
group of professionals who keep abreast of the ever-shifting trends in
energy and environmental markets and who are constantly working to provide
optimal solutions for the consumer. I’m pleased to be appointed to the
position of President and look forward to a strong future with HBS Bio,”
stated Claude Luster III, President of HBS BioEnergy.
In September of 2006, HBS created HBS BioEnergy, a wholly owned subsidiary
dedicated to the development facilities that produce ethanol and other
biofuels.
Human BioSystems is a developer of preservation platforms for organs and
other bio-materials. HBS is headquartered in Palo Alto, California with
research facilities in Michigan and has been granted four patents by the
U.S. Patent Office.
Contact:
Human BioSystems Investor Relations Investor Relations
Harry Masuda Yes International Concept Communications Group LLC
(650) 323-0943 Rich Kaiser James D. Caldwell
(800) 631-8127 (727) 447-0514
Certain statements contained herein are “forward-looking” statements (as
such term is defined in the Private Securities Litigation Reform Act of
1995). Because such statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, failure to obtain regulatory
approvals for the construction of ethanol plants, failure to obtain the
required financing and to construct the ethanol plants, failure of the
ethanol plants to meet standards, the inability to find raw material for
the production of ethanol or to sell the ethanol at on acceptable terms,
the risks involved in pursuing a business unrelated to HBS’ prior business,
and other factors discussed in filings made by the Company with the
Securities and Exchange Commission
(c)DGAP 11.10.2006
—————————————————————————
Latest News
Latest Reports
Upcoming Events
No Events found